CrystalsFirst

CrystalsFirsts MAGNET platform overcomes current limitations of small molecule drug discovery. Our proprietary structural biology technology detects molecular magnets and generative AI/Machine Learning identifies novel molecules and druggable binding pockets for difficult targets. Our MAGNET Platform is a unique and powerful approach to unlock chemical matter. It integrates the crystal structure first strategy, large-scale computational modelling, generative AI and medicinal chemistry. Starting with crystal structures as the first step in drug discovery, we also gain valuable insights into target interactions, enabling rational design from the beginning. Building block chemistry provides rapid access to diverse chemical scaffolds, facilitating hit expansion, scaffold...

Drug discovery,lead discovery,hit finding,structural biology,fragment-based drug discovery,fbdd,fbld,fragment-based lead discovery,crystallography,lead optimization,generative ai,machine learning,and virtual screening

Crystalsfirst operates in the Biotechnology research industry.

Crystalsfirst's revenue is 11m - 100m

Crystalsfirst has 11 - 50 employees.